Vivani Medical Inc

Vivani Medical maintains a debt-free capital structure with a debt-to-equity ratio of 0.0, supported by total equity of $15.73 million and cash and equivalents of $16.23 million against total assets of $39.39 million. The company holds a current liquidity position that is assessed as low risk, with no immediate filing-based liquidity flags detected. The market capitalization stands at $103.18 million, implying a price-to-book ratio of 6.56, which reflects a significant premium over tangible book value given the absence of intangible assets in the equity calculation.

Profitability metrics are deeply negative, with a return on equity of -169.16% and a return on assets of -67.55%, driven by an operating income of -$27.56 million and net income of -$26.61 million. The company reports zero revenue, indicating it is in a pre-commercial or early-stage development phase where costs are incurred without corresponding sales. The negative EV/EBITDA of -3.16 further underscores the lack of earnings generation. These figures are consistent with a biotech or medtech firm burning cash for research and development prior to product launch.

Segment and geographic data are not provided in the available financial snapshot, preventing a detailed analysis of revenue concentration or regional exposure. The absence of revenue data implies that no specific segment or geography currently contributes to the top line, or that such disclosures are not yet material or reported in the normalized period.

Growth trajectory cannot be assessed from historical periods as no prior annual or quarterly revenue or net income data is present in the input. The current state shows a static revenue base of zero, with the primary dynamic being the consumption of cash reserves, evidenced by an operating cash flow of -$24.32 million and capital expenditures of $1.17 million.

Risk assessment indicates low liquidity risk and low dilution risk, with no immediate flags for dilution sources such as ATM offerings or recent share issuances. The shares outstanding remain constant at 76.43 million for both basic and diluted counts, suggesting no current options or warrants are dilutive in the calculation. However, the high burn rate relative to cash reserves poses a long-term sustainability risk if revenue generation does not commence.

Recent observations include a sector classification re-analysis due to sector contamination, audited in July 2026. Analyst sentiment is moderately positive, with a mean recommendation of 2.00 (Buy), driven by four Buy ratings and no Hold or Strong Buy ratings. The mean price target is $4.62, with a median of $4.00, suggesting analysts expect significant upside from the current market price of $1.35, likely based on future product pipeline milestones rather than current financial performance.

Vivani Medical Inc (VANI.O) has seen a new investor, identified by investor ID 931, add a position of 1,200 shares as of March 31, 2026. This addition, detected on June 20, 2026, represents a nominal value of $0.001224 million and constitutes a negligible weight of approximately 0.0000006% of the company's equity. While the signal is classified as notable due to the change in holder composition, the absolute scale of the transaction is minimal. Concurrently, the company's internal analytical framework underwent significant revisions. The AI-driven narrative, business summary, and conclusion were all modified, with similarity scores dropping to 0.029 for the narrative and conclusion, and 0.154 for the business summary. Additionally, the key takeaways section saw a net neutral change, with seven new points added and seven removed. These updates suggest a substantial re-evaluation of the company's strategic positioning or operational outlook within the analytical model. Despite these internal shifts and the new holder activity, the broader market sentiment and news flow remain quiet. Cross-source signal data indicates zero news dispatches for Vivani Medical from June 24, 2026, through July 14, 2026. This absence of external commentary or sentiment shifts suggests that the recent changes are currently contained within the company's reporting structures and specific holder updates, rather than being driven by broader market events or public announcements. From a structural perspective, Vivani Medical continues to operate with no reported officers, no analyst coverage, and no index memberships. The company maintains a base of 11 top holders, indicating a concentrated but small shareholder base. The combination of revised internal analysis and a new, albeit tiny, institutional or individual stakeholder entry points to a period of quiet recalibration for the firm, absent any significant external catalysts or public market attention.

Operating income −4,0% YoY; Net income −7,6% YoY.

• ▍Operating income −4,0% YoY
• ▍Net income −7,6% YoY
• ▍Free cash flow −7,2% YoY

Operating income −5,4% YoY; Net income −9,6% YoY.

• ▍Operating income −5,4% YoY
• ▍Net income −9,6% YoY
• ▍Free cash flow −8,6% YoY

Operating income −6,6% YoY; Net income −8,1% YoY.

• ▍Operating income −6,6% YoY
• ▍Net income −8,1% YoY
• ▍Free cash flow −21,4% YoY

Operating income −31,4% YoY; Net income −33,4% YoY.

• ▍Operating income −31,4% YoY
• ▍Net income −33,4% YoY
• ▍Free cash flow −34,4% YoY

Operating income -$6.6M.

• ▍Operating income -$6.6M

Operating income -$6.5M.

• ▍Operating income -$6.5M

Operating income -$6.3M.

• ▍Operating income -$6.3M

Operating income −11,7% YoY; Net income −13,3% YoY.

• ▍Operating income −11,7% YoY
• ▍Net income −13,3% YoY
• ▍Free cash flow −15,7% YoY

Operating income +8,5% YoY; Net income +8,4% YoY.

• ▍Operating income +8,5% YoY
• ▍Net income +8,4% YoY
• ▍Free cash flow +9,6% YoY

Operating income −87,7% YoY; Net income −84,7% YoY.

• ▍Operating income −87,7% YoY
• ▍Net income −84,7% YoY
• ▍Free cash flow −89,0% YoY